IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada .

SOURCE Investment Industry Regulatory Organization of Canada (IIROC)

View original content: https://www.newswire.ca/en/releases/archive/June2022/09/c0692.html

News Provided by Canada Newswire via QuoteMedia

cse:lobe pharmaceutical investing

LOBE:CNX

Lobe Sciences Investor Kit

and hear about exciting investment opportunities.

Corporate info
Insights
Growth strategies
Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)

Investing News Network

26 August 2020

Lobe Sciences

Entering Clinical Stage Development for Proprietary Patent-pending Psilocin Compounds

Entering Clinical Stage Development for Proprietary Patent-pending Psilocin Compounds Keep Reading...

Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

Investing News Network

16 September 2025

Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

lobe sciences ltd. (CSE: LOBE,OTC:LOBEF) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming... Keep Reading...

Lobe Sciences Provides Update on L-130 Clinical Program

Investing News Network

07 December 2023

Lobe Sciences Provides Update on L-130 Clinical Program

Phase 1 results show significantly increased bioavailability for its stable psilocin compared to psilocybin L-130 Phase 2 Trial Planned for 2024 lobe sciences ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to... Keep Reading...

Lobe Sciences Provides Update on L-130 Oral Psilocin Compound

Investing News Network

05 December 2023

Lobe Sciences Provides Update on L-130 Oral Psilocin Compound

L-130 passes 12 months ongoing stability lobe sciences ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the Company's lead clinical asset, L-130, a proprietary stabilized... Keep Reading...

Lobe Sciences, Ltd. Announces The Appointment Of Mathew Lee As CFO

Investing News Network

18 September 2023

Lobe Sciences, Ltd. Announces The Appointment Of Mathew Lee As CFO

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases announced today that Mathew Lee will join the organization as Chief Financial... Keep Reading...

Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia & Company

Investing News Network

14 September 2023

Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia & Company

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases announced that on August 30, 2023 it signed an amendment to the share purchase... Keep Reading...

Glowing pills hover above a futuristic digital platform with blue light background.

Giann Liguid

13 January

DCVC, NVIDIA Back Proxima’s US$80 Million Bet on AI Drug Discovery

Artificial intelligence (AI) biotech startup Proxima has raised US$80 million in seed funding to accelerate the development of drugs that modulate protein-to-protein interactions.The financing round was led by Data Collective Venture Capital (DCVC), with participation from NVIDIA's (NASDAQ:NVDA)... Keep Reading...

Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Meagen Seatter

05 January

Top 5 Small-cap Pharma Stocks (Updated January 2026)

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval. However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected... Keep Reading...

Canada maple leaves on left and pharmaceutical pills in red and blue on right.

Meagen Seatter

05 January

5 Best-performing Canadian Pharma Stocks (Updated January 2026)

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are... Keep Reading...

Various colorful pills and tablets scattered from a brown bottle on a blue background.

Meagen Seatter

31 December 2025

Pharma Market Forecast: Top Trends for Pharma in 2026

The pharmaceutical sector is entering 2026 at a critical juncture. While recent initial public offering (IPO) performance has been stellar, with pharma firms claiming five of the top 10 IPO returns this year, the outlook next year is dominated by significant investment headwinds. Large,... Keep Reading...

InMed Announces Results of 2025 Annual General and Special Meeting

Investing News Network

17 December 2025

InMed Announces Results of 2025 Annual General and Special Meeting

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders... Keep Reading...

InMed Provides Update on BayMedica Commercial Business

Investing News Network

12 December 2025

InMed Provides Update on BayMedica Commercial Business

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement.Recently, H.R. 5371, the "Continuing... Keep Reading...